FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2739069498> ?p ?o ?g. }

• W2739069498 endingPage "2247" @default.
• W2739069498 startingPage "2241" @default.
• W2739069498 abstract "BackgroundEribulin is a microtubule dynamics inhibitor with a novel mechanism of action. This phase 3 study aimed to compare overall survival (OS) in patients with heavily pretreated non-small cell lung cancer (NSCLC) receiving eribulin to treatment of physician’s choice (TPC).Patients and methodsPatients with advanced NSCLC who had received ≥2 prior therapies, including platinum-based doublet and epidermal growth factor receptor tyrosine kinase inhibitor, were randomly assigned to receive eribulin or TPC (gemcitabine, pemetrexed, vinorelbine, docetaxel). The primary endpoint was OS. Secondary endpoints were progression-free survival and objective response rate.ResultsFive hundred and forty patients were randomized to either eribulin (n = 270) or TPC (n = 270). Median OS for eribulin and TPC was the same: 9.5 months [hazard ratio (HR): 1.16; 95% confidence interval: 0.95–1.41; P = 0.13]. Progression-free survival for eribulin and TPC was 3.0 and 2.8 months, respectively (HR: 1.09; 95% confidence interval: 0.90–1.32; P = 0.39). The objective response rate was 12% for eribulin and 15% for TPC. Clinical benefit rate (eribulin, 57%; TPC, 55%) and disease control rate (eribulin, 63%; TPC, 58%) were similar between treatment arms. The most common adverse event was neutropenia, which occurred in 57% of eribulin patients and 49% of TPC patients at all grades. Other non-hematologic side-effects were manageable and similar in both groups except for peripheral sensory neuropathy (all grades; eribulin, 16%; TPC, 9%).ConclusionThis phase 3 study did not demonstrate superiority of eribulin over TPC with regard to overall survival. However, eribulin does show activity in the third-line setting for NSCLC.Trial registration IDwww.ClinicalTrials.gov; NCT01454934." @default.
• W2739069498 created "2017-07-31" @default.
• W2739069498 creator A5013851334 @default.
• W2739069498 creator A5018054038 @default.
• W2739069498 creator A5020327537 @default.
• W2739069498 creator A5022022857 @default.
• W2739069498 creator A5029761367 @default.
• W2739069498 creator A5032459330 @default.
• W2739069498 creator A5034276209 @default.
• W2739069498 creator A5052962058 @default.
• W2739069498 creator A5057249839 @default.
• W2739069498 creator A5072917229 @default.
• W2739069498 creator A5087836238 @default.
• W2739069498 date "2017-09-01" @default.
• W2739069498 modified "2023-10-06" @default.
• W2739069498 title "A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer" @default.
• W2739069498 cites W2038934354 @default.
• W2739069498 cites W2054841768 @default.
• W2739069498 cites W2105026490 @default.
• W2739069498 cites W2109574241 @default.
• W2739069498 cites W2113779881 @default.
• W2739069498 cites W2114799287 @default.
• W2739069498 cites W2119366998 @default.
• W2739069498 cites W2121926293 @default.
• W2739069498 cites W2127152525 @default.
• W2739069498 cites W2127357802 @default.
• W2739069498 cites W2130629599 @default.
• W2739069498 cites W2130652363 @default.
• W2739069498 cites W2134667653 @default.
• W2739069498 cites W2137545466 @default.
• W2739069498 cites W2138297714 @default.
• W2739069498 cites W2259955047 @default.
• W2739069498 cites W2626223149 @default.
• W2739069498 cites W4234236664 @default.
• W2739069498 doi "https://doi.org/10.1093/annonc/mdx284" @default.
• W2739069498 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5834051" @default.
• W2739069498 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28911085" @default.
• W2739069498 hasPublicationYear "2017" @default.
• W2739069498 type Work @default.
• W2739069498 sameAs 2739069498 @default.
• W2739069498 citedByCount "11" @default.
• W2739069498 countsByYear W27390694982018 @default.
• W2739069498 countsByYear W27390694982019 @default.
• W2739069498 countsByYear W27390694982020 @default.
• W2739069498 countsByYear W27390694982021 @default.
• W2739069498 countsByYear W27390694982022 @default.
• W2739069498 countsByYear W27390694982023 @default.
• W2739069498 crossrefType "journal-article" @default.
• W2739069498 hasAuthorship W2739069498A5013851334 @default.
• W2739069498 hasAuthorship W2739069498A5018054038 @default.
• W2739069498 hasAuthorship W2739069498A5020327537 @default.
• W2739069498 hasAuthorship W2739069498A5022022857 @default.
• W2739069498 hasAuthorship W2739069498A5029761367 @default.
• W2739069498 hasAuthorship W2739069498A5032459330 @default.
• W2739069498 hasAuthorship W2739069498A5034276209 @default.
• W2739069498 hasAuthorship W2739069498A5052962058 @default.
• W2739069498 hasAuthorship W2739069498A5057249839 @default.
• W2739069498 hasAuthorship W2739069498A5072917229 @default.
• W2739069498 hasAuthorship W2739069498A5087836238 @default.
• W2739069498 hasBestOaLocation W27390694981 @default.
• W2739069498 hasConcept C121608353 @default.
• W2739069498 hasConcept C126322002 @default.
• W2739069498 hasConcept C143998085 @default.
• W2739069498 hasConcept C168563851 @default.
• W2739069498 hasConcept C203092338 @default.
• W2739069498 hasConcept C207103383 @default.
• W2739069498 hasConcept C2775930923 @default.
• W2739069498 hasConcept C2776387010 @default.
• W2739069498 hasConcept C2776694085 @default.
• W2739069498 hasConcept C2778239845 @default.
• W2739069498 hasConcept C2780350996 @default.
• W2739069498 hasConcept C44249647 @default.
• W2739069498 hasConcept C530470458 @default.
• W2739069498 hasConcept C71924100 @default.
• W2739069498 hasConceptScore W2739069498C121608353 @default.
• W2739069498 hasConceptScore W2739069498C126322002 @default.
• W2739069498 hasConceptScore W2739069498C143998085 @default.
• W2739069498 hasConceptScore W2739069498C168563851 @default.
• W2739069498 hasConceptScore W2739069498C203092338 @default.
• W2739069498 hasConceptScore W2739069498C207103383 @default.
• W2739069498 hasConceptScore W2739069498C2775930923 @default.
• W2739069498 hasConceptScore W2739069498C2776387010 @default.
• W2739069498 hasConceptScore W2739069498C2776694085 @default.
• W2739069498 hasConceptScore W2739069498C2778239845 @default.
• W2739069498 hasConceptScore W2739069498C2780350996 @default.
• W2739069498 hasConceptScore W2739069498C44249647 @default.
• W2739069498 hasConceptScore W2739069498C530470458 @default.
• W2739069498 hasConceptScore W2739069498C71924100 @default.
• W2739069498 hasIssue "9" @default.
• W2739069498 hasLocation W27390694981 @default.
• W2739069498 hasLocation W27390694982 @default.
• W2739069498 hasLocation W27390694983 @default.
• W2739069498 hasLocation W27390694984 @default.
• W2739069498 hasOpenAccess W2739069498 @default.
• W2739069498 hasPrimaryLocation W27390694981 @default.
• W2739069498 hasRelatedWork W1900595920 @default.
• W2739069498 hasRelatedWork W2019621848 @default.
• W2739069498 hasRelatedWork W2114624491 @default.

• next